Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa

Joslyn S. Kirby; Linnea Thorlacius; Jérémy Lambert; Valerie Ciaravino; Robert Rolleri; Ingrid Pansar; Edward Muller; Christopher G. Pelligra; John R. Ingram

doi:10.1093/bjd/ljaf067

Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL^©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa

Joslyn S. Kirby, Linnea Thorlacius, Jérémy Lambert, Valerie Ciaravino, Robert Rolleri, Ingrid Pansar, Edward Muller, Christopher G. Pelligra, John R. Ingram

Department of Dermatology

Research output: Contribution to journal › Article › peer-review

Abstract

Background Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition which negatively impacts patients' physical and mental wellbeing.

Original language	English (US)
Pages (from-to)	93-104
Number of pages	12
Journal	British Journal of Dermatology
Volume	193
Issue number	1
DOIs	https://doi.org/10.1093/bjd/ljaf067
State	Published - Jul 1 2025

All Science Journal Classification (ASJC) codes

Dermatology

Access to Document

10.1093/bjd/ljaf067

Fingerprint

Dive into the research topics of 'Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL^©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa'. Together they form a unique fingerprint.

Cite this

Kirby, J. S., Thorlacius, L., Lambert, J., Ciaravino, V., Rolleri, R., Pansar, I., Muller, E., Pelligra, C. G., & Ingram, J. R. (2025). Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL^©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa. British Journal of Dermatology, 193(1), 93-104. https://doi.org/10.1093/bjd/ljaf067

@article{a5172fda83f041c5885162639c718378,

title = "Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL{\textcopyright}) questionnaire using pooled data from the phase III BE HEARD I \& II trials of bimekizumab in hidradenitis suppurativa",

abstract = "Background Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition which negatively impacts patients' physical and mental wellbeing.",

author = "Kirby, \{Joslyn S.\} and Linnea Thorlacius and J{\'e}r{\'e}my Lambert and Valerie Ciaravino and Robert Rolleri and Ingrid Pansar and Edward Muller and Pelligra, \{Christopher G.\} and Ingram, \{John R.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2025.",

year = "2025",

month = jul,

day = "1",

doi = "10.1093/bjd/ljaf067",

language = "English (US)",

volume = "193",

pages = "93--104",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Oxford University Press",

number = "1",

}

Kirby, JS, Thorlacius, L, Lambert, J, Ciaravino, V, Rolleri, R, Pansar, I, Muller, E, Pelligra, CG & Ingram, JR 2025, 'Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL^©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa', British Journal of Dermatology, vol. 193, no. 1, pp. 93-104. https://doi.org/10.1093/bjd/ljaf067

Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL^©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa. / Kirby, Joslyn S.; Thorlacius, Linnea; Lambert, Jérémy et al.
In: British Journal of Dermatology, Vol. 193, No. 1, 01.07.2025, p. 93-104.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa

AU - Kirby, Joslyn S.

AU - Thorlacius, Linnea

AU - Lambert, Jérémy

AU - Ciaravino, Valerie

AU - Rolleri, Robert

AU - Pansar, Ingrid

AU - Muller, Edward

AU - Pelligra, Christopher G.

AU - Ingram, John R.

PY - 2025/7/1

Y1 - 2025/7/1

N2 - Background Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition which negatively impacts patients' physical and mental wellbeing.

AB - Background Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition which negatively impacts patients' physical and mental wellbeing.

UR - https://www.scopus.com/pages/publications/105008977439

UR - https://www.scopus.com/inward/citedby.url?scp=105008977439&partnerID=8YFLogxK

U2 - 10.1093/bjd/ljaf067

DO - 10.1093/bjd/ljaf067

M3 - Article

C2 - 40172122

AN - SCOPUS:105008977439

SN - 0007-0963

VL - 193

SP - 93

EP - 104

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 1

ER -

Kirby JS, Thorlacius L, Lambert J, Ciaravino V, Rolleri R, Pansar I et al. Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL^©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa. British Journal of Dermatology. 2025 Jul 1;193(1):93-104. doi: 10.1093/bjd/ljaf067